-+ 0.00%
-+ 0.00%
-+ 0.00%

Biovica signs lab services agreement with leading US cancer center for DiviTum TKa testing

PUBT·08/06/2026 07:00:48
Listen to the news
Biovica signs lab services agreement with leading US cancer center for DiviTum TKa testing
  • Biovica signed a laboratory services agreement with an NCI-designated U.S. Comprehensive Cancer Center.
  • Deal lets the center access DiviTum TKa testing via Biovica’s CLIA-certified laboratory in San Diego.
  • DiviTum TKa is an FDA 510(k)-cleared blood test to aid monitoring disease progression in HR-positive metastatic breast cancer.
  • Agreement expands availability at major U.S. cancer institutions, supporting broader clinical adoption.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.